scispace - formally typeset
F

Fulvio Mavilio

Researcher at University of Modena and Reggio Emilia

Publications -  228
Citations -  20283

Fulvio Mavilio is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Genetic enhancement & Viral vector. The author has an hindex of 68, co-authored 227 publications receiving 19200 citations. Previous affiliations of Fulvio Mavilio include Paris Descartes University & Vita-Salute San Raffaele University.

Papers
More filters
Journal ArticleDOI

Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid

TL;DR: The data indicate that homeobox-gene activation specifically accompanies RA-induced differentiation of NT2/D1 cells, thereby providing an excellent model for studying the molecular basis of homeOBox-Gene regulation and the possible role of the homeobbox in cell differentiation.
Journal ArticleDOI

Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts

TL;DR: A limited set of cryptic splice sites caused the majority of aberrant splicing events, providing a strategy for recoding lentiviral vector backbones and transgenes to reduce their potential posttranscriptional genotoxicity.
Journal ArticleDOI

Specificity of HOX protein function depends on DNA-protein and protein-protein interactions, both mediated by the homeo domain.

TL;DR: Affinity chromatography experiments show that the homeo domain amino terminus/helix 1 region is able to mediate direct interactions between HOX proteins in solution, which indicates that specificity of HOX protein function in vivo depends on both DNA-protein and protein-protein interactions, mediated by the same sub region of theHomeo domain.
Journal ArticleDOI

An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency

TL;DR: Retroviral vector gene transfer is necessary and sufficient for development of specific immune functions in vivo and has therapeutic potential to correct this lethal immunodeficiency.